Cathie Wood's ARK ETF announced daily trading for Thursday, April 4, 2024, revealing a series of strategic moves in the technology and biotech sectors. The most important transaction of the day was coinbase global Inc (NASDAQ:) sold a total of 25,662 shares across ARKK and ARKW ETFs for a total value of $6,456,046.
In contrast, ARK expressed bullish sentiment on Roblox, Inc. (NYSE:RBLX), purchasing 59,883 shares across three funds: ARKK, ARKW, and ARKF for a total of $2,182,136. The acquisition continues the trend that has been evident over the past week, elevating his ARK's standing in Roblox.
The other major transaction was the sale of 57,249 shares of Twilio Inc (NYSE:NYSE:) for a total value of $3,489,326. ARK has been selling its shares consistently in recent days, and this move is part of a broader pattern of reducing its exposure to Twilio.
ARK also acquired a significant position in 10X Genomics Inc (NASDAQ:TXG), purchasing 137,672 shares at $1 value for $5,004,376 across ARKK and ARKG ETFs. This acquisition is consistent with ARK's continued interest in the genomics space, as evidenced by previous transactions.
Furthermore, the arc Roku Inc (NASDAQ:) acquired 33,464 shares through the ARKW ETF for a total value of $2,082,130. This acquisition reflects ARK's continued confidence in the streaming device company.
Sofi Technologies Inc (NASDAQ:SOFI) also saw notable gains in ARK's portfolio, purchasing 166,792 shares worth $1,257,611 through the ARKF ETF. This purchase further strengthens ARK's recent accumulation of SOFI stock.
Includes small but strategic purchases Persona Ris Co., Ltd. (NASDAQ:) added 10,193 shares for $13,760 through the ARKG ETF alone, and Twist Bioscience Corp (NASDAQ:) acquired 23,499 shares across ARKK and the ARKG ETF for a total of $783,456.
Finally, ARK's interest in the biotech space was further highlighted with the purchase of 43,182 shares of Verve Therapeutics Inc (NASDAQ:VERV) through the ARKG ETF for an investment of $376,115.
Investors following ARK's trading activity should note continued trends, such as consistent buying in genomics-related stocks and reductions in positions in certain tech companies, that could be linked to market conditions and future growth. It may reflect ARK's strategic adjustments to its outlook.
This article was generated with the help of AI and reviewed by an editor. Please see our Terms of Use for more information.
